0

532296

GLENMARK

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GLENMARK PHARMACEUTICALS Share Price Today

GLENMARK PHARMACEUTICALS LTD. is currently trading at ₹2166, down by ₹18.89 from the previous close. The stock touched an intraday high of ₹2221.35 and a low of ₹2147.10 during the latest trading session. Over the past one year, GLENMARK PHARMACEUTICALS LTD. has delivered a return of 45.96%, while the stock has declined 8.68% in the last one month.

Investment Returns

Over 1 Month -8.68% Over 3 Months 2.89% Over 6 Months 10.37% Over 1 Year 45.96%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GLENMARK PHARMACEUTICALS fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 61,337.80
  • P/E Ratio (TTM) -306.87
  • Beta 0.63
  • Book Value / share 855.78
  • Return on equity 6.78%
  • EPS (TTM) 56.70
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -73.90
info icon alternate text

GLENMARK PHARMACEUTICALS Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 2207.56
Operating Expense 2193.08
Net Profit -73.90
Net Profit Margin (%) -3.34
Earnings Per Share (EPS) -2.62
EBITDA -29.36
Effective Tax Rate (%) 31.19
Particulars DEC 2025 (Values in Cr)
Revenue 2328.23
Operating Expense 1945.39
Net Profit 282.07
Net Profit Margin (%) 12.11
Earnings Per Share (EPS) 10.00
EBITDA 427.69
Effective Tax Rate (%) 18.60
Particulars SEP 2025 (Values in Cr)
Revenue 1219.53
Operating Expense 1798.99
Net Profit -739.19
Net Profit Margin (%) -60.61
Earnings Per Share (EPS) -26.19
EBITDA -824.04
Effective Tax Rate (%) 18.44
Particulars JUN 2025 (Values in Cr)
Revenue 2178.90
Operating Expense 1739.87
Net Profit 330.23
Net Profit Margin (%) 15.15
Earnings Per Share (EPS) 11.70
EBITDA 474.27
Effective Tax Rate (%) 17.68
Particulars MAR 2025 (Values in Cr)
Revenue 1909.94
Operating Expense 1737.63
Net Profit 147.76
Net Profit Margin (%) 7.73
Earnings Per Share (EPS) 5.24
EBITDA 249.82
Effective Tax Rate (%) 18.43
Particulars MAR 2026 (Values in Cr)
Revenue 7934.22
Operating Expense 7677.34
Net Profit -200.80
Net Profit Margin (%) -2.53
Earnings Per Share (EPS) -7.12
EBITDA 48.56
Effective Tax Rate (%) 24.53
Particulars MAR 2025 (Values in Cr)
Revenue 9010.54
Operating Expense 7249.58
Net Profit 1610.35
Net Profit Margin (%) 17.87
Earnings Per Share (EPS) 57.07
EBITDA 2421.38
Effective Tax Rate (%) 25.23
Particulars MAR 2024 (Values in Cr)
Revenue 7649.76
Operating Expense 7128.73
Net Profit 5167.29
Net Profit Margin (%) 67.54
Earnings Per Share (EPS) 183.13
EBITDA 7480.01
Effective Tax Rate (%) 26.18
Particulars MAR 2023 (Values in Cr)
Revenue 8019.67
Operating Expense 7138.86
Net Profit 1208.77
Net Profit Margin (%) 15.07
Earnings Per Share (EPS) 42.84
EBITDA 1962.84
Effective Tax Rate (%) 23.10
Particulars MAR 2022 (Values in Cr)
Revenue 8017.38
Operating Expense 6849.10
Net Profit 1997.79
Net Profit Margin (%) 24.91
Earnings Per Share (EPS) 70.80
EBITDA 2733.18
Effective Tax Rate (%) 14.53
Particulars MAR 2025 (Values in Cr)
Book Value / Share 313.60
ROE % 15.79
ROCE % 18.48
Total Debt to Total Equity 0.22
EBITDA Margin 18.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 278.11
ROE % -50.87
ROCE % 12.05
Total Debt to Total Equity 0.34
EBITDA Margin 17.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 335.75
ROE % 7.43
ROCE % 9.75
Total Debt to Total Equity 0.46
EBITDA Margin 16.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 322.03
ROE % 14.36
ROCE % 15.77
Total Debt to Total Equity 0.55
EBITDA Margin 20.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 250.37
ROE % 14.77
ROCE % 14.70
Total Debt to Total Equity 0.75
EBITDA Margin 19.91
Particulars MAR 2025 (Values in Cr)
Book Value / Share 868.35
ROE % 6.78
ROCE % 8.94
Total Debt to Total Equity 0.03
EBITDA Margin 26.24
Particulars MAR 2024 (Values in Cr)
Book Value / Share 814.01
ROE % 6.98
ROCE % 9.75
Total Debt to Total Equity 0.10
EBITDA Margin 30.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 633.57
ROE % 9.12
ROCE % 10.79
Total Debt to Total Equity 0.20
EBITDA Margin 29.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 593.21
ROE % 10.42
ROCE % 10.93
Total Debt to Total Equity 0.24
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 524.84
ROE % 11.77
ROCE % 12.39
Total Debt to Total Equity 0.26
EBITDA Margin 31.19
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1705.22
Total Assets 16049.55
Total Liabilities 16049.55
Total Equity 8849.07
Share Outstanding 28
Price to Book Ratio 1.77
Return on Assets (%) 6.52
Return on Capital (%) 9.48
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1659.45
Total Assets 14358.62
Total Liabilities 14358.62
Total Equity 7847.54
Share Outstanding 28
Price to Book Ratio 1.18
Return on Assets (%) -10.45
Return on Capital (%) -16.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1160.29
Total Assets 19371.67
Total Liabilities 19371.67
Total Equity 9839.25
Share Outstanding 28
Price to Book Ratio 0.73
Return on Assets (%) 1.53
Return on Capital (%) 2.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1411.51
Total Assets 17083.28
Total Liabilities 17083.28
Total Equity 9438.12
Share Outstanding 28
Price to Book Ratio 0.75
Return on Assets (%) 5.51
Return on Capital (%) 7.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1139.15
Total Assets 15603.57
Total Liabilities 15603.57
Total Equity 7064.27
Share Outstanding 28
Price to Book Ratio 0.89
Return on Assets (%) 6.21
Return on Capital (%) 8.25
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 132.74
Total Assets 28033.28
Total Liabilities 28033.28
Total Equity 24503.95
Share Outstanding 28
Price to Book Ratio 1.77
Return on Assets (%) 5.74
Return on Capital (%) 6.39
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 129.15
Total Assets 27414.39
Total Liabilities 27414.39
Total Equity 22970.62
Share Outstanding 28
Price to Book Ratio 1.18
Return on Assets (%) 18.84
Return on Capital (%) 21.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.79
Total Assets 24585.92
Total Liabilities 24585.92
Total Equity 17877.46
Share Outstanding 28
Price to Book Ratio 0.73
Return on Assets (%) 4.91
Return on Capital (%) 5.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.63
Total Assets 22914.48
Total Liabilities 22914.48
Total Equity 16738.58
Share Outstanding 28
Price to Book Ratio 0.75
Return on Assets (%) 8.71
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.78
Total Assets 20617.52
Total Liabilities 20617.52
Total Equity 14809.50
Share Outstanding 28
Price to Book Ratio 0.89
Return on Assets (%) 8.00
Return on Capital (%) 8.95
Particulars MAR 2025 (Values in Cr)
Net Income 1399.20
Cash from Operations -147.46
Cash from Investing 2.09
Cash from Financing 787.04
Net change in Cash -38.45
Free Cash Flow 602.09
Particulars MAR 2024 (Values in Cr)
Net Income 569.18
Cash from Operations 782.04
Cash from Investing 4560.89
Cash from Financing -3906.12
Net change in Cash 389.32
Free Cash Flow 1680.42
Particulars MAR 2023 (Values in Cr)
Net Income 868.45
Cash from Operations 1265.93
Cash from Investing -528.49
Cash from Financing -77.45
Net change in Cash 19.44
Free Cash Flow 1873.69
Particulars MAR 2022 (Values in Cr)
Net Income 1441.24
Cash from Operations 1667.09
Cash from Investing -333.28
Cash from Financing -520.49
Net change in Cash 254.88
Free Cash Flow 2457.21
Particulars MAR 2021 (Values in Cr)
Net Income 1382.47
Cash from Operations 1641.45
Cash from Investing -675.23
Cash from Financing -441.77
Net change in Cash 14.19
Free Cash Flow 2416.21
Particulars MAR 2025 (Values in Cr)
Net Income 2154.01
Cash from Operations 1171.67
Cash from Investing -489.51
Cash from Financing -95.41
Net change in Cash 3.86
Free Cash Flow 1512.62
Particulars MAR 2024 (Values in Cr)
Net Income 7000.74
Cash from Operations 375.64
Cash from Investing 3197.19
Cash from Financing -2666.44
Net change in Cash 35.29
Free Cash Flow 570.76
Particulars MAR 2023 (Values in Cr)
Net Income 1571.87
Cash from Operations 1890.48
Cash from Investing -431.46
Cash from Financing -978.49
Net change in Cash 64.09
Free Cash Flow 2080.10
Particulars MAR 2022 (Values in Cr)
Net Income 2337.44
Cash from Operations 1606.78
Cash from Investing -896.92
Cash from Financing -305.12
Net change in Cash 14.02
Free Cash Flow 1770.13
Particulars MAR 2021 (Values in Cr)
Net Income 1943.75
Cash from Operations 1579.25
Cash from Investing -1235.23
Cash from Financing -80.79
Net change in Cash -72.60
Free Cash Flow 1790.72
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 37.20 15.37 1.80 285.08 23.12 38.85
BLISS GVS PHARMA LTD 434.75 35.17 3.85 4599.18 118.35 442.20
CIPLA LTD 1378.90 27.30 3.23 111387.62 1165.55 1672.20
FERMENTA BIOTECH LIMITED 313.40 13.82 2.26 922.37 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 37.20 26.01 4.79 285.08 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 555.05 24.88 4.33 1604.68 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8719.05 113.87 24.97 21797.63 7630.00 10653.05
BLISS GVS PHARMA LTD 434.75 46.75 3.98 4599.18 118.35 442.20

GLENMARK PHARMACEUTICALS shareholding pattern

Holding
13.71%
46.65%
20.34%
19.28%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

GLENMARK PHARMACEUTICALS Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2173.55 -0.51 redarrow
red-green-graph indicator
13 Bearish
3 Bullish
  • 5 Days 2252.60
  • 26 Days 2301.30
  • 10 Days 2288.00
  • 50 Days 2261.90
  • 12 Days 2295.20
  • 100 Days 2177.40
  • 20 Days 2304.80
  • 200 Days 2057.00
2189.58 PIVOT
First Support 2139.72 First Resistance 2234.77 Second Support 2094.53 Second Resistance 2284.63 Third Support 2044.67 Third Resistance 2329.82
RSI 39.80 ADX 20.25 MACD -6.11 Williams % R -85.93 Commodity Channel Index (CCI) -226.91
Date 2026-06-02 Week 9428.00 Same Day 12810.00 Month 12726.00
1 Year 0.63 3 Year 0.75
Over 1 Month
-8.68% down
Over 1 Year
45.96% down
Over 3 Months
2.89% down
Over 3 Years
52.70% down
Over 6 Months
10.37% down
Over 5 Years
28.85% down

GLENMARK PHARMACEUTICALS Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
03 Oct 2025 2.5 Interim 03 Oct 2025 Equity shares
15 Sep 2025 2.5 Final 15 Sep 2025 Equity shares
13 Sep 2024 2.5 Final 17 Sep 2024 Equity shares
18 Sep 2023 2.5 Final 19 Sep 2023 Equity shares
12 Sep 2022 2.5 Final 14 Sep 2022 Equity shares
08 Sep 2021 2.5 Final 10 Sep 2021 Equity shares
17 Sep 2020 2.5 Final 19 Sep 2020 Equity shares
19 Sep 2019 2.0 Final 21 Sep 2019 Equity shares
19 Sep 2018 2.0 Final 22 Sep 2018 Equity shares
20 Sep 2017 2.0 Final 22 Sep 2017 Equity shares
03 Aug 2016 2.0 Final 05 Aug 2016 Equity shares
10 Sep 2015 2.0 Final 14 Sep 2015 Equity shares
10 Jul 2014 2.0 Final 14 Jul 2014 Equity shares
18 Jul 2013 2.0 Final 22 Jul 2013 Equity shares
19 Jul 2012 2.0 Final 23 Jul 2012 Equity shares
28 Jul 2011 0.4 Final 01 Aug 2011 Equity shares
16 Sep 2010 0.4 Final 20 Sep 2010 Equity shares
10 Sep 2009 0.4 Final 14 Sep 2009 Equity shares
07 Nov 2007 1.4 Interim 08 Nov 2007 Equity shares
04 Jan 2007 0.8 Interim 05 Jan 2007 Equity shares
27 Apr 2005 0.0 Interim 02 May 2005 Equity shares
Ex-Date Ex-Bonus Ratio
08 Mar 2005 04 Mar 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Sep 2007 2.0 1.0 17 Sep 2007
23 Oct 2003 10.0 2.0 31 Oct 2003

Top Gainers

Top Losers

Glenmark Share Result Highlights

ParticularsSep 2024 (Values in Cr)Jun 2024 (Values in Cr)Mar 2024 (Values in Cr)Sep 2023 (Values in Cr)
Revenue₹2594.89₹2296.88₹7649.76₹2170.40
Operating Expense₹1924.12₹1766.87₹7128.73₹1897.96
Net Profit₹595.06₹453.73₹5167.29₹302.35
Net Profit Margin22.93%19.75%67.54%13.93%
Earnings Per Share₹21.09₹16.08₹183.13₹10.72
EBITDA₹861.70₹686.75₹7480.01₹497.41
Effective Tax Rate25.15%26.61%26.18%22.34%

Key Highlights

  • Glenmark Pharmaceuticals has shown consistent growth in revenue and net profit, with a net profit margin of 22.93% for Q2 FY 2024.
  • The company reported an EBITDA of ₹861.70 Cr, indicating healthy operational performance.
  • Earnings Per Share (EPS) surged to ₹21.09 in Q2, demonstrating improved shareholder value.
  • The positive performance has contributed to the growth of the Glenmark Share Price, reflecting the company's solid financial health and potential for future returns.

Glenmark Share Annual Reports

ParticularsMar 2024 (Values in Cr)
Revenue₹7649.76
Operating Expense₹7128.73
Net Profit₹5167.29
Net Profit Margin67.54%
Earnings Per Share₹183.13
EBITDA₹7480.01
Effective Tax Rate26.18%

Key Highlights

  • Despite challenges in Dec 2023, Glenmark Pharmaceuticals showed an impressive turnaround by FY 2024, with revenue increasing to ₹7649.76 Cr.
  • The company posted a net profit of ₹5167.29 Cr in Mar 2024, marking a net profit margin of 67.54%, a significant recovery from the loss in Dec 2023.
  • The Earnings Per Share (EPS) improved dramatically to ₹183.13 in FY 2024, demonstrating robust growth in profitability, which positively influenced the Glenmark Share Price.

Glenmark Share Dividend

Ex-DateDividend Amount (₹)Dividend TypeRecord DateInstrument Type
18 Sep, 20232.5Final19 Sep, 2023Equity shares

Key Highlights

  • Consistent Payouts: Glenmark has issued both final and interim dividends over the years, demonstrating its financial strength and commitment to rewarding shareholders.
  • Recent Final Dividends: The company’s most recent final dividend of ₹2.5 per share was paid in 2023, following similar payouts in previous years.
  • Interim Dividends: Notably, Glenmark has also declared interim dividends, such as ₹1.4 in 2007 and ₹0.8 in 2007, showcasing its willingness to distribute earnings when appropriate during the year.
  • Shareholder Confidence: Both types of dividends illustrate the company's ongoing efforts to maintain investor confidence by sharing profits regularly, which positively impacts the Glenmark Share Price.

Popular FAQs

1. Who is the CEO of Glenmark Pharmaceuticals Ltd?

The current CEO of Glenmark Pharmaceuticals Ltd is Glenn Saldanha, who is also the Chairman and Managing Director of the company. He has been a key figure in shaping the growth and success of Glenmark since its inception in 1977, leading its transformation into a global pharmaceutical player.

 

2. When was Glenmark Pharmaceuticals Ltd established?

Glenmark Pharmaceuticals Ltd was established on November 18, 1977. Since then, it has grown significantly, expanding its operations in various therapeutic areas and becoming a prominent player in the global pharmaceutical industry.

 

3. What factors influence the Glenmark Share Price?

Several factors influence the Glenmark share price, including the company's financial performance, new product launches, regulatory approvals, global market expansion, and developments in their R&D pipeline, particularly in the oncology, respiratory, and dermatology sectors. Market sentiment and broader economic conditions also play a critical role.

 

4. Is Glenmark Pharmaceuticals Ltd debt-free?

No, Glenmark Pharmaceuticals Ltd is not completely debt-free. As of March 2024, its consolidated debt stands at INR 9.9 billion, a reduction from higher amounts in previous years. The company is actively working towards prepaying most of its long-term debt using proceeds from the sale of its API business while maintaining a solid liquidity profile.

 

5. What is the CAGR of Glenmark Share?

The Compound Annual Growth Rate (CAGR) of Glenmark share price is as follows:

  • 10 Years: 7%
  • 5 Years: 37%
  • 3 Years: 46%
  • 1 Year: 95%

This reflects significant growth in recent years, particularly driven by strong performance in key therapeutic areas.

 

6. How has the Glenmark Share Price performed over the past year?

The Glenmark share price has surged by approximately 95.23% over the past year, with a 52-week high of ₹1,830.05 and a low of ₹764.25. While the stock has experienced slight declines in recent months—with returns of -10.65% over the past three months and -8.45% over the last month—the overall long-term outlook remains positive, with analysts giving it a "Buy" rating.

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

Glenmark Pharmaceuticals Ltd share price is for NSE ₹ 2,174.00 & for BSE ₹ 2,173.55 as on Jun 03 2026 03:29 PM.

What is the Market Cap of Glenmark Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 61,337.80 as on Jun 03 2026 03:29 PM.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glenmark Pharmaceuticals Ltd for NSE is ₹ 2,474.00 and ₹ 1,448.50 and for BSE is ₹ 2,471.05 and ₹ 1,448.50.

What is 1 year return for Glenmark Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 45.96%.

What is the P/E Ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Jun 03 2026 03:29 PM the price-to-earnings (PE) ratio for Glenmark Pharmaceuticals Ltd share is -306.87.

What is the PB ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Jun 03 2026 03:29 PM, the price-to-book (PB) ratio for Glenmark Pharmaceuticals Ltd share is 855.78.

How to Buy Glenmark Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glenmark Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glenmark Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glenmark Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Glenmark Pharmaceuticals Ltd?

Answer Field

The current CEO of Glenmark Pharmaceuticals Ltd is Glenn Saldanha, who is also the Chairman and Managing Director of the company. He has been a key figure in shaping the growth and success of Glenmark since its inception in 1977, leading its transformation into a global pharmaceutical player.

When was Glenmark Pharmaceuticals Ltd established?

Answer Field

Glenmark Pharmaceuticals Ltd was established on November 18, 1977. Since then, it has grown significantly, expanding its operations in various therapeutic areas and becoming a prominent player in the global pharmaceutical industry.

What factors influence the Glenmark Share Price?

Answer Field

Several factors influence the Glenmark share price, including the company's financial performance, new product launches, regulatory approvals, global market expansion, and developments in their R&D pipeline, particularly in the oncology, respiratory, and dermatology sectors. Market sentiment and broader economic conditions also play a critical role.

Is Glenmark Pharmaceuticals Ltd debt-free?

Answer Field

No, Glenmark Pharmaceuticals Ltd is not completely debt-free. As of March 2024, its consolidated debt stands at INR 9.9 billion, a reduction from higher amounts in previous years. The company is actively working towards prepaying most of its long-term debt using proceeds from the sale of its API business while maintaining a solid liquidity profile.

What is the CAGR of Glenmark Share?

Answer Field

The Compound Annual Growth Rate (CAGR) of Glenmark share price is as follows:

  • 10 Years: 7%
  • 5 Years: 37%
  • 3 Years: 46%
  • 1 Year: 95%

This reflects significant growth in recent years, particularly driven by strong performance in key therapeutic areas.

How has the Glenmark Share Price performed over the past year?

Answer Field

The Glenmark share price has surged by approximately 95.23% over the past year, with a 52-week high of ₹1,830.05 and a low of ₹764.25. While the stock has experienced slight declines in recent months—with returns of -10.65% over the past three months and -8.45% over the last month—the overall long-term outlook remains positive, with analysts giving it a "Buy" rating.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|